The spectrum of action includes many Gram-positive and Gram-negative bacteria (including Pseudomonas) and anaerobic bacteria. The overall spectrum is similar to that of imipenem, although<unk>  is more active against Enterobacteriaceae and less active against Gram-positive bacteria. It works against extended-spectrum β-lactamases, but may be more susceptible to metallo-β-lactamases.<unk>  is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with hematological malignancies and cancer patients receiving anticancer drugs that suppress bone marrow formation. It is approved for complicated skin and skin structure infections, complicated intra-abdominal infections and bacterial meningitis. In 2017, the U.S. Food and Drug Administration (FDA) granted approval for the combination of<unk>  and vaborbactam to treat adults with complicated urinary tract infections. Administration<unk>  is administered intravenously as a white crystalline powder to be dissolved in 5% monobasic potassium phosphate solution. Dosing must be adjusted for altered kidney function and for haemofiltration. As with other ß-lactams antibiotics, the effectiveness of treatment depends on the amount of time during the dosing interval that the<unk>  concentration is above the minimum inhibitory concentration for the bacteria causing the infection. For ß-lactams, including<unk> , prolonged intravenous administration is associated with lower mortality than bolus intravenous infusion in persons with whose infections are severe, or caused by bacteria that are less sensitive to<unk> , such as Pseudomonas aeruginosa.
Meropenem
Resistin
Vancomycin
Imipenem
Aztreonam
Ertapenem
Imipenem/cilastatin/relebactam
Colistin